|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123 JPY | 0.00% |
|
-3.15% | -8.89% |
| Apr. 01 | Chiome Bioscience Cancels License Agreements with ADC Therapeutics | MT |
| Feb. 13 | Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited | CI |
Chiome Bioscience Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was JPY 358.89 million compared to JPY 278.21 million a year ago. Net loss was JPY 663.66 million compared to JPY 771.01 million a year ago.
Basic loss per share from continuing operations was JPY 13.7 compared to JPY 18.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.89% | 43.53M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
CHIOME BIOSCIENCE INC. 
